000283132 001__ 283132
000283132 005__ 20260105112800.0
000283132 0247_ $$2doi$$a10.1002/ana.27250
000283132 0247_ $$2pmid$$apmid:40285625
000283132 0247_ $$2pmc$$apmc:PMC12174725
000283132 0247_ $$2ISSN$$a0364-5134
000283132 0247_ $$2ISSN$$a1531-8249
000283132 037__ $$aDZNE-2026-00028
000283132 041__ $$aEnglish
000283132 082__ $$a610
000283132 1001_ $$aMüller, Laura$$b0
000283132 245__ $$aElevated α-Synuclein Aggregate Levels in the Urine of Patients with Isolated REM Sleep Behavior Disorder and Parkinson's Disease.
000283132 260__ $$aHoboken, NJ$$bWiley-Blackwell$$c2025
000283132 3367_ $$2DRIVER$$aarticle
000283132 3367_ $$2DataCite$$aOutput Types/Journal article
000283132 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1767608833_32744
000283132 3367_ $$2BibTeX$$aARTICLE
000283132 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000283132 3367_ $$00$$2EndNote$$aJournal Article
000283132 520__ $$aParkinson's disease (PD) is a neurodegenerative disorder characterized by α-synuclein aggregation in neurons. Recent advances suggest α-synuclein aggregates could serve as a biomarker for PD and related synucleinopathies. This study used surface-based fluorescence intensity distribution analysis (sFIDA) to measure α-synuclein aggregates in urine. Patients with PD and isolated rapid eye movement sleep behavior disorder, a precursor to PD, had elevated concentrations compared with healthy controls. Sensitivity and specificity were 83% and 65% for PD versus controls and 89% and 62% for isolated rapid eye movement sleep behavior disorder versus controls. The findings highlight sFIDA's potential for diagnosing synucleinopathies. ANN NEUROL 2025;98:147-151.
000283132 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000283132 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000283132 650_7 $$2NLM Chemicals$$aalpha-Synuclein
000283132 650_7 $$2NLM Chemicals$$aBiomarkers
000283132 650_2 $$2MeSH$$aHumans
000283132 650_2 $$2MeSH$$aParkinson Disease: urine
000283132 650_2 $$2MeSH$$aParkinson Disease: diagnosis
000283132 650_2 $$2MeSH$$aREM Sleep Behavior Disorder: urine
000283132 650_2 $$2MeSH$$aREM Sleep Behavior Disorder: diagnosis
000283132 650_2 $$2MeSH$$aalpha-Synuclein: urine
000283132 650_2 $$2MeSH$$aMale
000283132 650_2 $$2MeSH$$aFemale
000283132 650_2 $$2MeSH$$aMiddle Aged
000283132 650_2 $$2MeSH$$aAged
000283132 650_2 $$2MeSH$$aBiomarkers: urine
000283132 650_2 $$2MeSH$$aSensitivity and Specificity
000283132 7001_ $$aÖzdüzenciler, Pelin$$b1
000283132 7001_ $$aSchedlich-Teufer, Charlotte$$b2
000283132 7001_ $$aSeger, Aline$$b3
000283132 7001_ $$00000-0003-3041-1583$$aJergas, Hannah$$b4
000283132 7001_ $$00000-0002-8230-1856$$aFink, Gereon R$$b5
000283132 7001_ $$aWillbold, Dieter$$b6
000283132 7001_ $$0P:(DE-2719)9003277$$aSommerauer, Michael$$b7$$udzne
000283132 7001_ $$aBarbe, Michael T$$b8
000283132 7001_ $$0P:(DE-2719)2810376$$aTamgüney, Gültekin$$b9
000283132 773__ $$0PERI:(DE-600)2037912-2$$a10.1002/ana.27250$$gVol. 98, no. 1, p. 147 - 151$$n1$$p147 - 151$$tAnnals of neurology$$v98$$x0364-5134$$y2025
000283132 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9003277$$aExternal Institute$$b7$$kExtern
000283132 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000283132 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-18$$wger
000283132 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-18$$wger
000283132 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANN NEUROL : 2022$$d2024-12-18
000283132 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000283132 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000283132 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-18
000283132 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-18
000283132 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000283132 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-18
000283132 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000283132 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-18
000283132 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-18
000283132 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-18
000283132 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000283132 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000283132 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bANN NEUROL : 2022$$d2024-12-18
000283132 980__ $$ajournal
000283132 980__ $$aI:(DE-2719)1040260
000283132 9801_ $$aEXTERN4VITA